ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -6 مورد

Telmisartan and hydrochlorothiazide: Drug information

Telmisartan and hydrochlorothiazide: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Telmisartan and hydrochlorothiazide: Patient drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Fetal toxicity:

Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, discontinue therapy as soon as possible.

Brand Names: US
  • Micardis HCT
Brand Names: Canada
  • Micardis Plus
Pharmacologic Category
  • Angiotensin II Receptor Blocker;
  • Antihypertensive;
  • Diuretic, Thiazide
Dosing: Adult
Hypertension

Hypertension: Oral:

Replacement therapy: Combination product can be substituted for individual titrated agents.

Initiation of combination therapy when monotherapy has failed to achieve desired effects:

Patients currently on telmisartan monotherapy: Initial dose if blood pressure is not currently controlled on telmisartan 80 mg monotherapy: Telmisartan 80 mg/hydrochlorothiazide 12.5 mg once daily; manufacturer labeling suggests that dose may be titrated up to telmisartan 160 mg/hydrochlorothiazide 25 mg once daily if blood pressure remains uncontrolled after 2 to 4 weeks of therapy; however, in mild to moderate hypertension, doses of telmisartan >80 mg were not associated with a greater reduction in blood pressure (Ref).

Patients currently on hydrochlorothiazide monotherapy: Initial dose if blood pressure is not currently controlled on hydrochlorothiazide 25 mg once daily monotherapy or patients who experience hypokalemia while on hydrochlorothiazide 25 mg monotherapy: Telmisartan 80 mg/hydrochlorothiazide 12.5 mg once daily; manufacturer labeling suggests that dose may be titrated up to telmisartan 160 mg/hydrochlorothiazide 25 mg once daily if blood pressure remains uncontrolled after 2 to 4 weeks of therapy; however, in mild to moderate hypertension, doses of telmisartan >80 mg were not associated with a greater reduction in blood pressure (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

CrCl >30 mL/minute: No dosage adjustment necessary.

CrCl ≤30 mL/minute: Not recommended.

Dosing: Liver Impairment: Adult

Mild to moderate hepatic impairment or biliary obstructive disorders: Initial: Telmisartan 40 mg/hydrochlorothiazide 12.5 mg once daily

Severe hepatic impairment: Not recommended.

Dosing: Older Adult

Refer to adult dosing. Monitor renal function.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see individual agents.

1% to 10%:

Dermatologic: Erythema of skin (<2%)

Gastrointestinal: Abdominal pain (<2%), diarrhea (3%), dyspepsia (<2%), nausea (2%), vomiting (<2%)

Nervous system: Dizziness (5%), fatigue (3%)

Neuromuscular & skeletal: Back pain (<2%)

Renal: Increased blood urea nitrogen (3%), increased serum creatinine (1%)

Respiratory: Bronchitis (<2%), flu-like symptoms (2%), pharyngitis (<2%), sinusitis (4%), upper respiratory tract infection (8%)

Postmarketing:

Cardiovascular: Edema, orthostatic hypotension, syncope, tachycardia

Dermatologic: Fixed drug eruption, skin rash, toxicoderma, urticaria

Endocrine & metabolic: Hypoglycemia, hyponatremia

Genitourinary: Erectile dysfunction

Hematologic & oncologic: Eosinophilia

Hepatic: Hepatic impairment

Hypersensitivity: Anaphylaxis, angioedema

Nervous system: Asthenia, headache, vertigo

Neuromuscular & skeletal: Increased creatine phosphokinase in blood specimen, rhabdomyolysis

Renal: Acute kidney injury, renal failure syndrome

Respiratory: Cough

Contraindications

Hypersensitivity to telmisartan, hydrochlorothiazide, or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus; anuria.

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Note: Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged.

Canadian labeling: Additional contraindications (not in US labeling): Concomitant use with aliskiren in patients with moderate-to-severe renal impairment (GFR <60 mL/minute/1.73 m2); pregnancy; breastfeeding; fructose intolerance; galactose intolerance (eg, galactosaemia, congenital Lactase deficiency, glucose-galactose malabsorption).

Warnings/Precautions

Concerns related to adverse effects:

• Angioedema: Angioedema has been reported rarely with some angiotensin II receptor antagonists (ARBs) and may occur at any time during treatment (especially following first dose). It may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). Patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE-inhibitor therapy may be at an increased risk. Prolonged frequent monitoring may be required, especially if tongue, glottis, or larynx are involved, as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Discontinue therapy immediately if angioedema occurs. Aggressive early management is critical. Intramuscular (IM) administration of epinephrine may be necessary. Do not readminister to patients who have had angioedema with ARBs.

• Electrolyte disturbances: Hyperkalemia may occur with angiotensin II receptor antagonists; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.

• Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide. This risk may be increased with doses ≥25 mg (Gurwitz 1997).

• Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.

• Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with telmisartan/hydrochlorothiazide.

• Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Additional treatments may be needed if uncontrolled intraocular pressure persists. Risk factors may include a history of sulfonamide or penicillin allergy.

• Photosensitivity: May occur with hydrochlorothiazide.

• Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.

• Skin cancer, nonmelanoma: Prolonged use (≥3 years) may increase the risk for squamous cell carcinoma up to 4 times and increase the risk for basal cell carcinoma up to 1.25 times compared to patients not treated with hydrochlorothiazide (Pedersen 2018; Pottegård 2017).

• Sulfonamide (“sulfa”) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO2NH2). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.

Disease-related concerns:

• Aortic/mitral stenosis: Use telmisartan with caution in patients with significant aortic/mitral stenosis.

• Bariatric surgery: Dehydration: Avoid diuretics in the immediate postoperative period after bariatric surgery; electrolyte disturbances and dehydration may occur. Diuretics may be resumed, if indicated, once oral fluid intake goals are met (Ziegler 2009).

• Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.

• Hepatic impairment: Use with caution in patients who have biliary obstructive disorders or hepatic impairment. In progressive or severe hepatic disease, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy/coma.

• Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.

• Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.

• Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use; should be discontinued prior to testing for parathyroid function.

• Renal artery stenosis: Use telmisartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.

• Renal impairment: Use with caution in patients with mild or moderate renal impairment; use is not recommended in severe renal impairment.

• Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.

Special populations:

• Pregnancy: [US Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.

• Surgical patients: In patients on chronic angiotensin receptor blocker (ARB) therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; however, discontinuation of therapy prior to surgery is controversial. If continued preoperatively, avoidance of hypotensive agents during surgery is prudent (Hillis, 2011).

Dosage form specific issues:

• Sorbitol: Some products may contain sorbitol.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, oral:

Micardis HCT:

40/12.5: Telmisartan 40 mg and hydrochlorothiazide 12.5 mg

80/12.5: Telmisartan 80 mg and hydrochlorothiazide 12.5 mg

80/25: Telmisartan 80 mg and hydrochlorothiazide 25 mg

Generic:

40/12.5: Telmisartan 40 mg and hydrochlorothiazide 12.5 mg

80/12.5: Telmisartan 80 mg and hydrochlorothiazide 12.5 mg

80/25: Telmisartan 80 mg and hydrochlorothiazide 25 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Micardis HCT Oral)

40-12.5 mg (per each): $5.61

80-12.5 mg (per each): $5.61

80-25 mg (per each): $5.61

Tablets (Telmisartan-HCTZ Oral)

40-12.5 mg (per each): $4.83 - $5.52

80-12.5 mg (per each): $4.83 - $5.52

80-25 mg (per each): $4.83 - $5.52

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, oral:

Micardis Plus:

80/12.5: Telmisartan 80 mg and hydrochlorothiazide 12.5 mg

80/25: Telmisartan 80 mg and hydrochlorothiazide 25 mg

Administration: Adult

Administer without regard to meals.

Use: Labeled Indications

Hypertension: Management of hypertension (monotherapy or in combination with other antihypertensives). See individual monographs.

Limitations of use: Not indicated for initial therapy.

Medication Safety Issues
Older Adult: High-Risk Medication:

Beers Criteria: Diuretics (hydrochlorothiazide) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).

Metabolism/Transport Effects

Refer to individual components.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Agents with Clinically Relevant Anticholinergic Effects: May increase serum concentration of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Ajmaline: Sulfonamides may increase adverse/toxic effects of Ajmaline. Specifically, the risk for cholestasis may be increased. Risk C: Monitor

Alcohol (Ethyl): May increase orthostatic hypotensive effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Alfuzosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Aliskiren: May increase nephrotoxic effects of Angiotensin II Receptor Blockers. Aliskiren may increase hyperkalemic effects of Angiotensin II Receptor Blockers. Aliskiren may increase hypotensive effects of Angiotensin II Receptor Blockers. Management: Aliskiren use with ACEIs or ARBs in patients with diabetes is contraindicated. Combined use in other patients should be avoided, particularly when CrCl is less than 60 mL/min. If combined, monitor potassium, creatinine, and blood pressure closely. Risk D: Consider Therapy Modification

Allopurinol: Thiazide and Thiazide-Like Diuretics may increase hypersensitivity effects of Allopurinol. Risk C: Monitor

Amifostine: Blood Pressure Lowering Agents may increase hypotensive effects of Amifostine. Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine. Risk D: Consider Therapy Modification

Aminolevulinic Acid (Systemic): Photosensitizing Agents may increase photosensitizing effects of Aminolevulinic Acid (Systemic). Risk X: Avoid

Aminolevulinic Acid (Topical): Photosensitizing Agents may increase photosensitizing effects of Aminolevulinic Acid (Topical). Risk C: Monitor

Amphetamines: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Angiotensin II: Angiotensin II Receptor Blockers may decrease therapeutic effects of Angiotensin II. Risk C: Monitor

Angiotensin-Converting Enzyme Inhibitors: Angiotensin II Receptor Blockers may increase adverse/toxic effects of Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor Blockers may increase serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: Use of telmisartan and ramipril is not recommended. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. Consider alternatives when possible. Monitor blood pressure, renal function, and potassium if combined. Risk D: Consider Therapy Modification

Antidiabetic Agents: Hyperglycemia-Associated Agents may decrease therapeutic effects of Antidiabetic Agents. Risk C: Monitor

Antidiabetic Agents: Thiazide and Thiazide-Like Diuretics may decrease therapeutic effects of Antidiabetic Agents. Risk C: Monitor

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may increase hypotensive effects of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor

Arginine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Arsenic Trioxide: Thiazide and Thiazide-Like Diuretics may increase hypotensive effects of Arsenic Trioxide. Thiazide and Thiazide-Like Diuretics may increase QTc-prolonging effects of Arsenic Trioxide. Management: When possible, avoid concurrent use of arsenic trioxide with drugs that can cause electrolyte abnormalities, such as the thiazide and thiazide-like diuretics. Risk D: Consider Therapy Modification

Barbiturates: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Benperidol: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Beta2-Agonists: May increase hypokalemic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Bile Acid Sequestrants: May decrease absorption of Thiazide and Thiazide-Like Diuretics. Management: Separate administration of bile acid sequestrants and oral thiazide diuretics by at least 4 hours. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant. Risk D: Consider Therapy Modification

Brigatinib: May decrease antihypertensive effects of Antihypertensive Agents. Brigatinib may increase bradycardic effects of Antihypertensive Agents. Risk C: Monitor

Brimonidine (Topical): May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Bromperidol: May decrease hypotensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase hypotensive effects of Bromperidol. Risk X: Avoid

Calcium Salts: Thiazide and Thiazide-Like Diuretics may increase serum concentration of Calcium Salts. Risk C: Monitor

Cardiac Glycosides: Telmisartan may increase serum concentration of Cardiac Glycosides. Risk C: Monitor

Corticosteroids (Systemic): May increase hypokalemic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

CycloPHOSphamide: Thiazide and Thiazide-Like Diuretics may increase adverse/toxic effects of CycloPHOSphamide. Specifically, granulocytopenia may be enhanced. Risk C: Monitor

Dapoxetine: May increase orthostatic hypotensive effects of Angiotensin II Receptor Blockers. Risk C: Monitor

Desmopressin: Hyponatremia-Associated Agents may increase hyponatremic effects of Desmopressin. Risk C: Monitor

Dexketoprofen: May increase adverse/toxic effects of Sulfonamides. Risk C: Monitor

Dexmethylphenidate: May decrease therapeutic effects of Antihypertensive Agents. Risk C: Monitor

Diacerein: May increase therapeutic effects of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased. Risk C: Monitor

Diazoxide Choline: May increase adverse/toxic effects of Thiazide and Thiazide-Like Diuretics. Specifically, the hyperglycemic and hyperuricemic effects may be increased. Risk C: Monitor

Diazoxide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Diazoxide: Thiazide and Thiazide-Like Diuretics may increase adverse/toxic effects of Diazoxide. Risk C: Monitor

Dichlorphenamide: Thiazide and Thiazide-Like Diuretics may increase hypokalemic effects of Dichlorphenamide. Risk C: Monitor

Dipeptidyl Peptidase-IV Inhibitors: May increase adverse/toxic effects of Angiotensin II Receptor Blockers. Specifically, the risk for angioedema may be increased with this combination. Risk C: Monitor

Dofetilide: HydroCHLOROthiazide may increase QTc-prolonging effects of Dofetilide. HydroCHLOROthiazide may increase serum concentration of Dofetilide. Risk X: Avoid

Drospirenone-Containing Products: May increase hyperkalemic effects of Angiotensin II Receptor Blockers. Risk C: Monitor

DULoxetine: Blood Pressure Lowering Agents may increase hypotensive effects of DULoxetine. Risk C: Monitor

EPINEPHrine (Systemic): Diuretics may increase arrhythmogenic effects of EPINEPHrine (Systemic). Diuretics may decrease vasopressor effects of EPINEPHrine (Systemic). Risk C: Monitor

Finerenone: Angiotensin II Receptor Blockers may increase hyperkalemic effects of Finerenone. Risk C: Monitor

Flunarizine: May increase therapeutic effects of Antihypertensive Agents. Risk C: Monitor

Heparin: May increase hyperkalemic effects of Angiotensin II Receptor Blockers. Risk C: Monitor

Heparins (Low Molecular Weight): May increase hyperkalemic effects of Angiotensin II Receptor Blockers. Risk C: Monitor

Herbal Products with Blood Pressure Increasing Effects: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Herbal Products with Blood Pressure Lowering Effects: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Hypotension-Associated Agents: Blood Pressure Lowering Agents may increase hypotensive effects of Hypotension-Associated Agents. Risk C: Monitor

Iloperidone: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Indoramin: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Ipragliflozin: May increase adverse/toxic effects of Thiazide and Thiazide-Like Diuretics. Specifically, the risk for intravascular volume depletion may be increased. Risk C: Monitor

Isocarboxazid: May increase antihypertensive effects of Antihypertensive Agents. Risk X: Avoid

Isocarboxazid: May increase hypotensive effects of Diuretics. Risk X: Avoid

Ivabradine: Thiazide and Thiazide-Like Diuretics may increase arrhythmogenic effects of Ivabradine. Risk C: Monitor

Levodopa-Foslevodopa: Blood Pressure Lowering Agents may increase hypotensive effects of Levodopa-Foslevodopa. Risk C: Monitor

Levosulpiride: Thiazide and Thiazide-Like Diuretics may increase adverse/toxic effects of Levosulpiride. Risk X: Avoid

Licorice: May increase hypokalemic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Lithium: Angiotensin II Receptor Blockers may increase serum concentration of Lithium. Management: Initiate lithium at lower doses in patients receiving an angiotensin II receptor blocker (ARB). Consider lithium dose reductions in patients stable on lithium therapy who are initiating an ARB. Monitor lithium concentrations closely when combined. Risk D: Consider Therapy Modification

Lithium: Thiazide and Thiazide-Like Diuretics may decrease excretion of Lithium. Management: Reduce the lithium dose if coadministered with thiazide or thiazide-like diuretics. Monitor serum lithium levels during coadministration with thiazide and thiazide-like diuretics. Risk D: Consider Therapy Modification

Loop Diuretics: May increase hypotensive effects of Angiotensin II Receptor Blockers. Loop Diuretics may increase nephrotoxic effects of Angiotensin II Receptor Blockers. Risk C: Monitor

Loop Diuretics: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Lormetazepam: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Mecamylamine: Thiazide and Thiazide-Like Diuretics may increase adverse/toxic effects of Mecamylamine. Management: Consider avoiding the use of mecamylamine and thiazide diuretics. If combined, mecamylamine prescribing information suggests reducing the mecamylamine dose by 50% in order to avoid excessive hypotension. Risk D: Consider Therapy Modification

Metergoline: May decrease antihypertensive effects of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may increase orthostatic hypotensive effects of Metergoline. Risk C: Monitor

Methenamine: Thiazide and Thiazide-Like Diuretics may decrease therapeutic effects of Methenamine. Risk C: Monitor

Methotrexate: HydroCHLOROthiazide may increase nephrotoxic effects of Methotrexate. Risk C: Monitor

Methoxsalen (Systemic): Photosensitizing Agents may increase photosensitizing effects of Methoxsalen (Systemic). Risk C: Monitor

Methylphenidate: May decrease antihypertensive effects of Antihypertensive Agents. Risk C: Monitor

Molsidomine: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Multivitamins/Fluoride (with ADE): May increase hypercalcemic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide and Thiazide-Like Diuretics may increase hypercalcemic effects of Multivitamins/Minerals (with ADEK, Folate, Iron). Risk C: Monitor

Multivitamins/Minerals (with AE, No Iron): Thiazide and Thiazide-Like Diuretics may increase serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, thiazide diuretics may decrease the excretion of calcium, and continued concomitant use can also result in metabolic alkalosis. Risk C: Monitor

Mycophenolate: Telmisartan may decrease serum concentration of Mycophenolate. Risk C: Monitor

Naftopidil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Neuromuscular-Blocking Agents (Nondepolarizing): Thiazide and Thiazide-Like Diuretics may increase neuromuscular-blocking effects of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor

Nicergoline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nicorandil: May increase hyperkalemic effects of Angiotensin II Receptor Blockers. Risk C: Monitor

Nicorandil: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Nitroprusside: Blood Pressure Lowering Agents may increase hypotensive effects of Nitroprusside. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents (Topical): May decrease therapeutic effects of Angiotensin II Receptor Blockers. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents (Topical): May decrease therapeutic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents: May decrease therapeutic effects of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function. Angiotensin II Receptor Blockers may increase adverse/toxic effects of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Risk C: Monitor

Nonsteroidal Anti-Inflammatory Agents: May decrease therapeutic effects of Thiazide and Thiazide-Like Diuretics. Thiazide and Thiazide-Like Diuretics may increase nephrotoxic effects of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor

Obinutuzumab: May increase hypotensive effects of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider Therapy Modification

Opioid Agonists: May increase adverse/toxic effects of Diuretics. Opioid Agonists may decrease therapeutic effects of Diuretics. Risk C: Monitor

Palopegteriparatide: Thiazide and Thiazide-Like Diuretics may increase therapeutic effects of Palopegteriparatide. Thiazide and Thiazide-Like Diuretics may decrease therapeutic effects of Palopegteriparatide. Risk C: Monitor

Patiromer: May decrease serum concentration of Telmisartan. Management: Administer telmisartan at least 3 hours before or 3 hours after patiromer. Risk D: Consider Therapy Modification

Pentoxifylline: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Perazine: May increase hypotensive effects of Antihypertensive Agents. Risk C: Monitor

Pholcodine: Blood Pressure Lowering Agents may increase hypotensive effects of Pholcodine. Risk C: Monitor

Phosphodiesterase 5 Inhibitors: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Piperacillin: May increase hypokalemic effects of Diuretics. Risk C: Monitor

Polyethylene Glycol-Electrolyte Solution: Angiotensin II Receptor Blockers may increase nephrotoxic effects of Polyethylene Glycol-Electrolyte Solution. Risk C: Monitor

Polyethylene Glycol-Electrolyte Solution: Diuretics may increase nephrotoxic effects of Polyethylene Glycol-Electrolyte Solution. Risk C: Monitor

Porfimer: Photosensitizing Agents may increase photosensitizing effects of Porfimer. Risk X: Avoid

Potassium Salts: May increase hyperkalemic effects of Angiotensin II Receptor Blockers. Risk C: Monitor

Potassium-Sparing Diuretics: May increase hyperkalemic effects of Angiotensin II Receptor Blockers. Risk C: Monitor

Prazosin: Antihypertensive Agents may increase hypotensive effects of Prazosin. Risk C: Monitor

Promazine: Thiazide and Thiazide-Like Diuretics may increase QTc-prolonging effects of Promazine. Risk X: Avoid

Prostacyclin Analogues: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Quinagolide: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Ranolazine: May increase adverse/toxic effects of Angiotensin II Receptor Blockers. Risk C: Monitor

Reboxetine: May increase hypokalemic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Sacubitril: Angiotensin II Receptor Blockers may increase adverse/toxic effects of Sacubitril. Risk X: Avoid

Selective Serotonin Reuptake Inhibitor: May increase hyponatremic effects of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor

Silodosin: May increase hypotensive effects of Blood Pressure Lowering Agents. Risk C: Monitor

Sodium Phosphates: Angiotensin II Receptor Blockers may increase nephrotoxic effects of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Risk C: Monitor

Sodium Phosphates: Diuretics may increase nephrotoxic effects of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Risk C: Monitor

Sotagliflozin: HydroCHLOROthiazide may decrease therapeutic effects of Sotagliflozin. Sotagliflozin may decrease serum concentration of HydroCHLOROthiazide. Risk C: Monitor

Sparsentan: May increase adverse/toxic effects of Angiotensin II Receptor Blockers. Risk X: Avoid

Tacrolimus (Systemic): Angiotensin II Receptor Blockers may increase hyperkalemic effects of Tacrolimus (Systemic). Risk C: Monitor

Terazosin: Antihypertensive Agents may increase hypotensive effects of Terazosin. Risk C: Monitor

Tolvaptan: May increase hyperkalemic effects of Angiotensin II Receptor Blockers. Risk C: Monitor

Topiramate: Thiazide and Thiazide-Like Diuretics may increase hypokalemic effects of Topiramate. Thiazide and Thiazide-Like Diuretics may increase serum concentration of Topiramate. Risk C: Monitor

Toremifene: Thiazide and Thiazide-Like Diuretics may increase hypercalcemic effects of Toremifene. Risk C: Monitor

Trimethoprim: May increase hyperkalemic effects of Angiotensin II Receptor Blockers. Risk C: Monitor

Urapidil: Antihypertensive Agents may increase hypotensive effects of Urapidil. Risk C: Monitor

Verteporfin: Photosensitizing Agents may increase photosensitizing effects of Verteporfin. Risk C: Monitor

Vitamin D Analogs: Thiazide and Thiazide-Like Diuretics may increase hypercalcemic effects of Vitamin D Analogs. Risk C: Monitor

Food Interactions

See individual agents.

Pregnancy Considerations

[US Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected. Also see individual agents.

Breastfeeding Considerations

Hydrochlorothiazide is present in breast milk; it is not known if telmisartan is present. Due to the potential for adverse events in the breastfed infant, breastfeeding is not recommended by the manufacturer. Also see individual agents.

Monitoring Parameters

Blood pressure; serum electrolytes, BUN, creatinine

Mechanism of Action

Telmisartan: Telmisartan is an angiotensin receptor antagonist. Angiotensin II acts as a vasoconstrictor. In addition to causing direct vasoconstriction, angiotensin II also stimulates the release of aldosterone. Once aldosterone is released, sodium as well as water are reabsorbed. The end result is an elevation in blood pressure. Telmisartan binds to the AT1 angiotensin II receptor. This binding prevents angiotensin II from binding to the receptor thereby blocking the vasoconstriction and the aldosterone secreting effects of angiotensin II.

Hydrochlorothiazide: Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions

Pharmacokinetics (Adult Data Unless Noted)

See individual agents.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Micardis plus;
  • (AR) Argentina: Bertel d | Gliosartan plus | Micardis plus | Sactan d | Taroplen D;
  • (AT) Austria: Micardisplus | Telhycar | Telmicard plus hct | Telmisartan/hydrochlorothiazid accord | Telmisartan/Hydrochlorothiazid stada;
  • (AU) Australia: Micardis plus | Telmisartan/hct sandoz;
  • (BD) Bangladesh: Arbitel plus | Presart HZ | Telcardis plus | Telma plus | Telmilok plus | Telmipres plus | Telmitan plus | Tems plus;
  • (BE) Belgium: Kinzalkomb | Micardis plus | Telmisartan hctz teva | Telmisartan/Hydrochloorthiazide Sandoz;
  • (BF) Burkina Faso: Telmikaa h;
  • (BG) Bulgaria: Actelsar HCT | Co telsart | Micardis plus | Pritor plus | Tanydon HCT | Telmimed plus | Telmisartan/hidroclorotiazida egis | Telmotens plus | Telsol plus | Tezeo hct;
  • (BR) Brazil: Bramicar hct | Micardis hct | Pritor hct | Telmisartana + hidroclorotiazida | Tersocor hct | Vesuvius hct;
  • (CH) Switzerland: Co telmisartan sandoz | Co telmisartan spirig hc | Kinzalplus | Micardis plus | Telmisartan hct mepha | Telmisartan HCT Zentiva;
  • (CI) Côte d'Ivoire: Arbitel h | Telmikaa h | Telmis h;
  • (CL) Chile: Corasol d | Micardis plus | Tellmi d | Tensuren d;
  • (CN) China: Telmisartan and hydrochlorothiazide | Ti mi sha tan qing lv sai qin | Wen le ning;
  • (CO) Colombia: Cardixil hct | Micardis plus | Renangio plus | Telma-h | Temiltar h | Xifen H;
  • (CZ) Czech Republic: Micardisplus | Telmisartan/hydrochlorothiazid auxilto | Telmisartan/hydrochlorothiazid egis | Telmisartan/Hydrochlorothiazid ratiopharm | Telmisartan/hydrochlorothiazid sandoz | Telmisartan/hydrochlorothiazid xantis | Telmisartan/hydrochlorothiazide billev | Telmisartan/hydrochlorothiazide liconsa | Telmizek combi | Tezeo hct;
  • (DE) Germany: Actelsar HCT | Kinzalkomb | Micardis plus | Micardisplus | Micarid plus | Telmisartan / HCT axunio | Telmisartan comp. | Telmisartan/hct heumann | Telmisartan/hct mylan | Telmisartan/HCTZ AXiromed | Telmisartan/hydrochlorothiazid micro labs | Telmisartan/Hydrochlorothiazid Zentiva | Telmisartan/hydrochlorothiazide accord;
  • (DO) Dominican Republic: Telx d | Telx h | Telx plus | Telydalt plus;
  • (EC) Ecuador: Corazox plus | Cordiax D | Indivan hct | Indivan hct forte | Indivan htc | Micardis plus | Tellmi d | Telma 80h | Telma 80h plus | Telma h | Telmisartan 80 mg + hidroclorotiazida 12,5 mg tabletas. nifa | Telmisartan 80mg + hidroclorotiazida 12.5 mg tabletas. medigener | Telsar hc | Temiltar h | Tensuren d;
  • (EE) Estonia: Pritor plus | Telmisartan/hydrochlorothiazid tad | Telmisartan/hydrochlorothiazide billev | Telmisartan/hydrochlorothiazide sandoz | Telmisartan/hydrochlorothiazide teva pharma | Tezeo hct;
  • (EG) Egypt: Chartoreg plus | Micardis plus;
  • (ES) Spain: Actelsar HCT | Micardis plus | Pritor plus | Telmisartan / hidroclorotiazida apotex | Telmisartan/Hidroclorotiazida Alter | Telmisartan/hidroclorotiazida apotex | Telmisartan/hidroclorotiazida cinfa | Telmisartan/hidroclorotiazida combix | Telmisartan/hidroclorotiazida kern pharma | Telmisartan/hidroclorotiazida mabo | Telmisartan/hidroclorotiazida mylan pharmaceuticals | Telmisartan/hidroclorotiazida pensa | Telmisartan/hidroclorotiazida qualigen | Telmisartan/hidroclorotiazida ratio | Telmisartan/hidroclorotiazida sandoz | Telmisartan/hidroclorotiazida stada genericos | Telmisartan/hidroclorotiazida tarbis | Telmisartan/hidroclorotiazida tecnigen | Telmisartan/hidroclorotiazida teva pharma;
  • (ET) Ethiopia: Safetelmi H | Telmisartan and hydrochlorothiazide | Telmiswift H;
  • (FI) Finland: Kinzalkomb | Lesamor | Micardisplus | Telmisartan hydrochlorothiazide chemo iberica | Telmisartan/hydrochlorothiazid accord | Telmisartan/hydrochlorothiazide orion | Telmisartan/hydrochlorothiazide ratiopharm;
  • (FR) France: Micardisplus | Pritorplus | Telmisartan/hydrochlorothiazide actavis | Telmisartan/hydrochlorothiazide biogaran | Telmisartan/hydrochlorothiazide cristers | Telmisartan/hydrochlorothiazide eg | Telmisartan/hydrochlorothiazide Mylan | Telmisartan/hydrochlorothiazide sandoz | Telmisartan/hydrochlorothiazide teva sante | Telmisartan/hydrochlorothiazide zydus;
  • (GB) United Kingdom: Actelsar HCT | Micardis plus | Telmisartan and hydrochlorothiazide | Telmisartan/hydrochlorothiazide;
  • (GR) Greece: Actelsar HCT | Micardis plus | Pritor plus | Telmisartan/hydrochlorothiazide sandoz;
  • (HK) Hong Kong: Micardis plus;
  • (HR) Croatia: Micardisplus | Osan Plus | Pritorplus;
  • (HU) Hungary: Micardis plus | Pritor plus | Tanydon HCT | Telmisartan/hct teva | Tezeo hct | Tolucombi;
  • (ID) Indonesia: Micardis plus;
  • (IE) Ireland: Actelsar HCT | Micardis plus | Telmisartan/hydrochlorothiazide | Telmisartan/hydrochlorothiazide clonmel | Telmisartan/hydrochlorothiazide rowa;
  • (IN) India: Acmetel h | Altelsa plus | Angitel h | Arbitel h | Axeten H | Bp tel h | Cardiomart h | Cortel h | Cresar h | Ecotel H | Elzen h | Eritel-h | Gloritel H | Hisartan | Hitarget-H | Holytel h | Hytel H | Inditel H | Miotel h | Mytel h | Newtel H | Ozotel H | Revosart h | Safetelmi H | Sartel H | T let h | T press h | Targit H | Tazloc H | Tekaira 40 h | Tel tel h | Telblok H | Telca H | Teldil H | Teleact D | Telelak 40h | Telesort h | Telexia h | Telhim h | Teli h | Telimed h | Telindia h | Teliquest h | Telismart h | Telista-H | Tellme h | Tellzy h | Telma-h | Telmasurge H | Telmate h | Telmichek H | Telmigood h | Telmigraf h | Telmikaa h | Telmikind H | Telmilix h | Telmiluv h | Telmin h | Telminex H | Telminorm H | Telmiprime h | Telmiride h | Telmirise h | Telmirite h | Telmisafe h | Telmisat H | Telmisave h | Telmisurge h | Telmitop-hc | Telmitrust H | Telmivas H | Telmivib h | Telmiwell ht | Telmiwohn h | Telmkind h | Telmore h | Telnyle h | Telodil h | Telong H | Telpic-H | Telpil H | Telpin h | Telpres-h | Telsar-h | Telsart h | Telsartan h | Telsat h | Telsite h | Telstar h | Teltab-H | Teltop h | Telvas h | Telzox h | Temax H | Temsan H | Temsi h | Terelate h | Tetan-h | Tht-D | Tilan h | Tlm h | Tmt ht | Tsart H | Vitel h | Vritel h | Xadotel h | Xstan H | Yogatel h | Zitelmi-h;
  • (IS) Iceland: Actelsar HCT;
  • (IT) Italy: Lesamor | Micardis plus | Pritorplus | Taclomisar | Telmisartan e idroclorotiazide accord | Telmisartan e idroclorotiazide alter | Telmisartan e idroclorotiazide doc generici | Telmisartan e idroclorotiazide eg | Telmisartan e idroclorotiazide pensa | Telmisartan e idroclorotiazide teva italia;
  • (JO) Jordan: Micardis plus;
  • (JP) Japan: Micombi Combination | Telthia combination ap dsep | Telthia combination bp dsep | Telthia sawai;
  • (KE) Kenya: Arbitel h | Cilzec plus | Co micardis | Co tasmi | Glentel 40 h | Glentel 80 h | Ontel h | Teli h | Tellzy h | Telmed h | Telmi amh | Telmi h | Telmicos h | Telmikaa h | Telmitan h | Telsart h | Telswift h | Teltas h | Teltas lh | Unitel h;
  • (KR) Korea, Republic of: Anatel plus | Bertelplus | Cellmi plus | Cirtelmi plus | Dongkoo telmisartan plus | Hypertelmiplus | J telmi plus | Micatan plus | Mikaone | Mikaone plus | Mirtel plus | Mirto plus | Misartan plus | Monospin plus | Pritor plus | T sartan plus | Telcadi plus | Telito plus | Telmeil plus | Telmi on plus | Telmi plus | Telmibeta plus | Telmicall plus | Telmicure plus | Telmimore | Telmir plus | Telmira plus | Telmirotan plus | Telmisplus | Telmista plus | Telmitension plus | Telmiz plus | Telosartan plus | Telsar plus | Teltanzid | Tertan plus | Tesartan plus | Tezaltan Plus | Yuyu telmitaplu | Yuyu telmitaplus;
  • (KW) Kuwait: Micardis plus;
  • (LB) Lebanon: Micardis plus | Telmicard plus;
  • (LT) Lithuania: Actelsar HCT | Pritor plus | Telmisartan/hctz | Telmisartan/hydrochlorothiazide billev | Telmisartan/hydrochlorothiazide sandoz | Telsartan h | Tezeo hct;
  • (LU) Luxembourg: Kinzalkomb | Micardis plus | Telmisartan/Hydrochloorthiazide Sandoz;
  • (LV) Latvia: Actelsar HCT | Pritor plus | Telmisartan/hydrochlorothiazide tad | Telmisartan/hydrochlorothiazide teva pharma | Tezeo hct;
  • (MX) Mexico: Archer compuesto | Armilare hos | Bledromin | Frepadan pro | Lesprek h | Macamen | Micardis plus | Predxal plus | Rolet sup | Telarteq urti | Telicev syn | Telmisartan and hidroclorotiazida bioresearch | Telmisartan and hydrochlorothiazide | Temithor dual | Teprecom | Transendis hd | Transendis hid;
  • (MY) Malaysia: Micardis plus | Teli h;
  • (NG) Nigeria: Cortel h | Poccotel | Saftelmi h | Telduret | Telma-h | Telmisartan and hydrochlorothiazide | Telsart hct | Tramitz h;
  • (NL) Netherlands: Actelsar HCT | Kinzalkomb | Micardis plus | Telmisartan/hct | Telmisartan/hct cf | Telmisartan/hct teva | Telmisartan/hydrochloorthiazide accord | Telmisartan/hydrochloorthiazide glenmark | Telmisartan/Hydrochloorthiazide Mylan | Telmisartan/Hydrochloorthiazide Sandoz | Telmisartan/hydrochloorthiazide xiromed | Tolucombi;
  • (NO) Norway: Actelsar HCT | Micardis plus | Micardisplus;
  • (PE) Peru: Cordiax D | Micardis plus | Rematral hc | Renangio plus | Teleact hct | Telminor plus | Telzaar plus | Temisar plus;
  • (PH) Philippines: Micardis plus | Pritor plus | Telzyd h;
  • (PK) Pakistan: Co telbar | Co Telsan | Co tiocardis | Cotelsar | Cresar h | De Nile Plus | Mictel plus | Misar h | Misartan h | Normisar Plus | Telmis h | Telsarta D | Telsitan H | Telsitan h forte | Telzide | Telzimed | Velmon h | Winsartan plus;
  • (PL) Poland: Actelsar HCT | Gisartan | Polsart plus | Telhyd | Telmidon | Telmisartan + HCT Genoptim | Telmisartan/hydrochlorothiazide billev | Telmix plus | Telmizek combi | Telmizek hct | Tezeo hct | Tolucombi | Toptelmi hct | Zanacodar combi;
  • (PR) Puerto Rico: Micardis hct | Telmisartan and hydrochlorothiazide;
  • (PT) Portugal: Actelsar HCT | Micardis plus | Pritorplus | Telmisartan + Hidroclorotiazida Alter | Telmisartan + hidroclorotiazida Aristo | Telmisartan + Hidroclorotiazida Ciclum | Telmisartan + Hidroclorotiazida Generis | Telmisartan + Hidroclorotiazida Pharmakern | Telmisartan + hidroclorotiazida sandoz | Telmisartan + Hidroclorotiazida Teva | Telmisartan + hidroclorotiazida tolife | Telmisartan + hidroclorotiazida zentiva | Telmisartan+Hidroclorotiazida Ratiopharm | Telmisartan/hidroclorotiazida bluepharma;
  • (PY) Paraguay: Isquelium d | Karima d | Micardis plus | Nimicor d | Presolol d | Prilartan d | Tellmi d | Temisar plus;
  • (QA) Qatar: Micardis Plus;
  • (RO) Romania: Actelsar HCT | Telhycar | Tezeo hct;
  • (RU) Russian Federation: Micardisplus | Mikafor | Telmisartan H Stada | Telmista h | Telpres plus | Telsartan h | Telzap plus;
  • (SA) Saudi Arabia: Lisart plus | Micardis plus;
  • (SE) Sweden: Actelsar HCT | Kinzalkomb | Lesamor;
  • (SG) Singapore: Micardis plus;
  • (SI) Slovenia: Actelsar HCT | Micardis plus | Tolucombi;
  • (SK) Slovakia: Actelsar HCT | Micardisplus | Telmisartan/Hydrochlorotiazid EGIS | Telmisartan/hydrochlorotiazid sandoz | Telmisartan/hydrochlorotiazid xantis | Telmizek combi | Tezeo hct | Tolucombi;
  • (TH) Thailand: Micardis plus;
  • (TN) Tunisia: Telmycor plus;
  • (TR) Turkey: Micardis plus | Pritor plus | Telmiday plus | Telvis Plus | Tenvia;
  • (UA) Ukraine: Arbitel h | Micardis plus | Telmista h 40 | Telmista h 80 | Telmista hd 80 | Telpres plus | Telsartan h;
  • (UG) Uganda: Arbitel h | Aristo telvas h | Safetelmi H | Sartel H | Teli h | Telswift h | Teltas 40 h | Telvas h;
  • (UY) Uruguay: Micardisplus | Taroplen D | Temisar plus;
  • (VE) Venezuela, Bolivarian Republic of: Micardis plus;
  • (VN) Viet Nam: Mibetel hct | Mibetel plus | Telzid | Zhekof hct;
  • (ZA) South Africa: Cardiz Co | Cardtense Co | Co micardis | Co pritor | Co telza | Hartel co | Telpres plus | Tesar co | Tremistan plus;
  • (ZM) Zambia: Teli h | Telma-h | Telmikaa h;
  • (ZW) Zimbabwe: Telmi h | Teltas 40 h
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy. 2004;24(7):856-870. [PubMed 15303450]
  3. Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol. 1997;50(8):953-959. [PubMed 9291881]
  4. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011, 124(23):2610-42. [PubMed 22064600]
  5. Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. Ann Pharmacother. 2005;39(2):290-301. [PubMed 15644481]
  6. Micardis HCT (telmisartan/hydrochlorothiazide) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; December 2022.
  7. Micardis Plus (telmisartan/hydrochlorothiazide) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd; October 2022.
  8. Pedersen SA, Gaist D, Schmidt SAJ, Hölmich LR, Friis S, Pottegård A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673-681. doi: 10.1016/j.jaad.2017.11.042. [PubMed 29217346]
  9. Pottegård A, Hallas J, Olesen M, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med. 2017;282(4):322-331. doi: 10.1111/joim.12629. [PubMed 28480532]
  10. Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am. 2004;24(3):477-490. [PubMed 15242722]
  11. Smith DH, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol. 2000;40(12 pt 1):1380-1390. [PubMed 11185637]
  12. Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermatitis. 2004;51(2):57-62. [PubMed 15373844]
  13. Ziegler O, Sirveaux MA, Brunaud L, Reibel N, Quilliot D. Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies. Diabetes Metab. 2009;35(6, pt 2):544-557. doi: 10.1016/S1262-3636(09)73464-0. [PubMed 20152742]
Topic 9509 Version 293.0